AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca PLC reported that SVP, Group Controller Mani Sharma acquired 2.0000 Ordinary Shares on August 6, 2026 through a non-derivative grant under the Issuer's Share Incentive Plan. The shares were priced at GBP121.26 ($163.3400) using a GBP1.0000 to $1.3470 conversion rate, bringing direct holdings to 19267.4659 shares.
AstraZeneca PLC admitted 8,855 additional Ordinary Shares of $0.25 each to trading on the London Stock Exchange Main Market. These fully fungible shares were issued under the company’s employee share schemes between 1 July 2026 and 31 July 2026 pursuant to an existing block admission dated 29 January 2021. Following this admission, AstraZeneca has 1,551,033,389 Ordinary Shares in issue.
AstraZeneca PLC reports an updated share capital and voting rights position in line with UK disclosure rules. As at 31 July 2026, the company’s issued share capital with voting rights consists of 1,551,033,389 ordinary shares of US$0.25 each.
No shares are held in Treasury, so the total number of voting rights is also 1,551,033,389. Shareholders may use this figure as the denominator to assess whether they must notify interests or changes in interests under the Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca reports that Datroway (datopotamab deruxtecan), co-developed with Daiichi Sankyo, has been approved in the European Union as a 1st-line monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. It is described as the only TROP2-directed antibody drug conjugate in the EU demonstrating an overall survival benefit in this setting.
The approval is based on the Phase III TROPION-Breast02 trial in 644 patients, where Datroway improved median overall survival by 5.0 months to 23.7 months versus 18.7 months with chemotherapy (hazard ratio 0.79; p=0.0291) and reduced the risk of disease progression or death by 43% (hazard ratio 0.57; p<0.0001). Objective response rate was 62.5% versus 29.3% with chemotherapy, and the safety profile was consistent with prior studies. Datroway is now included in ESMO Clinical Practice Guidelines as a Category IA 1st-line option and has received an ESMO Magnitude of Clinical Benefit Scale score of 4 out of 5.
AstraZeneca delivered solid H1 2026 results, with Total Revenue of $30,672m, up 9% (6% at constant exchange rates), and Q2 revenue of $15,384m, up 6%. Oncology led growth, generating $14,124m (46% of Total Revenue, up 18%), and Rare Disease revenue rose to $4,911m, up 13%. In contrast, Cardiovascular, Renal & Metabolism revenue declined 8% to $6,089m, reflecting loss of exclusivity and pricing pressures. Reported EPS reached $3.60 (up 4%), while Core EPS rose 12% to $5.21. Q2 Gross Margin was 84%, one percentage point higher year on year.
The company reaffirmed full‑year 2026 guidance at constant exchange rates, expecting Total Revenue to grow by a mid‑to‑high single‑digit percentage and Core EPS by a low double‑digit percentage, with a Core Tax rate of 18‑22%. If June 2026 exchange rates persist, management anticipates a low single‑digit positive FX impact on Total Revenue. Net cash inflow from operating activities was $6,224m (down from $7,099m), while Net debt increased by $3,538m to $26,912m, reflecting higher investment, including capital expenditure of $1,513m. The Group intends to raise the annual dividend to $3.30 per share in FY 2026.
Strategically, AstraZeneca signed an exclusive licence for lung‑cancer medicine Zegfrovy (sunvozertinib) from Dizal, with a $600m upfront payment and up to $900m in milestones, plus tiered royalties. It also licensed respiratory candidate TQC3721 from Sino Biopharmaceutical, with a $200m upfront payment and milestones up to $1.9bn. R&D momentum included six positive Phase III programmes and multiple new approvals, such as Baxfendy in US hypertension, alongside setbacks including the CARDIO‑TTRansform trial for Wainua in ATTR‑CM not meeting its primary endpoint. Management reiterated confidence in the pipeline and its ambition to reach $80bn in Total Revenue by 2030.
AstraZeneca’s Alexion rare disease unit reported mixed Phase III results for Ultomiris (ravulizumab) in haematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In adults and adolescents, the randomised, placebo-controlled ALXN1210-TMA-313 trial did not achieve statistical significance on the primary endpoint of event-free survival through 26 weeks, although a trend toward treatment benefit was observed.
By contrast, the open-label paediatric ALXN1210-TMA-314 Phase III study showed overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks. Based on these data and the external real-world control study ALX-TMA-502, Alexion is advancing regulatory filings for Ultomiris in paediatric HSCT-TMA while continuing discussions with health authorities on potential next steps for the adult indication.
The safety profile across both Phase III studies was consistent with the known safety profile of Ultomiris and with that seen in patients undergoing HSCT. Ultomiris has Orphan Drug Designation in the US and Japan for HSCT-TMA and US Breakthrough Therapy designation for paediatric HSCT-TMA, a rare complication estimated to affect fewer than 6,000 people in the US.
AstraZeneca reported positive high-level Phase III results from the global CLARITY-Gastric01 trial, where sonesitatug vedotin (Sone-Ve) showed a statistically significant and highly clinically meaningful improvement in overall survival versus investigator's choice in 2nd and later-line CLDN18.2-positive advanced gastric, gastroesophageal junction and oesophageal adenocarcinoma cancers. The trial met a dual primary endpoint of overall survival in 3rd and later-line treatment and a key secondary endpoint of overall survival in the overall 2nd and later-line population, while progression-free survival showed an improvement trend but did not reach statistical significance.
Eligibility was based on CLDN18.2 expression in at least 25% of tumour cells, a threshold estimated to include about 60% of gastric/GEJ cancers and roughly 183,500 2nd and later-line patients annually in the US, EU, China and Japan. Sone-Ve was well tolerated with no new safety signals and is described as a potential first-in-class CLDN18.2-targeting antibody drug conjugate, supported by Orphan Drug Designation in the US and EU and Breakthrough Designation in China. AstraZeneca plans to present the data at a medical meeting and share them with global regulatory authorities.
AstraZeneca PLC reports that Etcamah (camizestrant) plus a CDK4/6 inhibitor has been approved in the European Union for 1st-line treatment of adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with emergent ESR1 mutation and no disease progression on endocrine therapy in combination with a CDK4/6 inhibitor.
Approval is based on the Phase III SERENA-6 trial, where the Etcamah combination reduced the risk of disease progression or death by 56% versus an aromatase inhibitor plus CDK4/6 inhibitor (hazard ratio 0.44; median progression-free survival 16.0 vs 9.2 months). A subsequent analysis showed time to second disease progression of 25.7 vs 19.1 months (hazard ratio 0.63), while overall survival data continue to mature in favour of the Etcamah combination.
Safety was consistent with the known profiles of the component medicines, with no new safety concerns and low, similar discontinuation rates. Etcamah is described as the first next-generation oral SERD and complete ER antagonist approved in this 1st-line setting and can be used with all widely approved CDK4/6 inhibitors. It is already approved in Japan, the United Arab Emirates and Saudi Arabia and is AstraZeneca’s 11th new medicine of the 20 expected to launch by 2030.
AstraZeneca PLC has entered an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for certain lung cancer patients. AstraZeneca will obtain worldwide rights to develop and commercialise Zegfrovy, paying Dizal $600m upfront and up to $900m in development, regulatory and sales-related milestones, plus tiered royalties on global sales. The transaction is expected to close in the second half of 2026, subject to customary conditions, and does not affect AstraZeneca’s 2026 financial guidance.
Zegfrovy is already approved in the US and China for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations whose disease has progressed after platinum-based chemotherapy. Dizal has reported positive Phase III WU-KONG28 results in 1st-line NSCLC with these mutations, supporting Supplemental New Drug Applications filed with the US FDA and China’s CDE, both of which have granted Breakthrough Therapy Designation for this setting. Zegfrovy is included in the NCCN NSCLC Guidelines as a Category 2A subsequent therapy option, and AstraZeneca positions it as complementing its existing EGFR-focused lung cancer portfolio.
AstraZeneca PLC reported that the CARDIO-TTRansform Phase III trial of Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet its primary efficacy endpoint. Adding Wainua to standard care did not significantly reduce the composite of cardiovascular mortality and recurrent cardiovascular events through Week 140 versus placebo.
Wainua was generally well tolerated with a safety profile consistent with earlier data. A prespecified subgroup on Wainua monotherapy showed fewer composite events with a nominally significant result, while patients already on stabiliser therapy showed no treatment effect. The trial enrolled 1,432 participants across 20 countries, randomised to 45 mg Wainua or placebo every four weeks, and full data will be shared at the European Society of Cardiology Congress in August 2026.